Cannabis cultivator Halo Labs Inc. has closed its acquisition of Nasalbinoid Natural Devices Corp.
The Toronto company acquired 34 million common shares for about CA$5.1 million ($3.6 million), or about 15 cents per share.
The company obtained approval from Neo Exchange Inc. for the Acquisition and the Concurrent Financing.
Halo Labs has made a series of announcements in recent weeks.
The company is planning a pilot distillate manufacturing program in California for resin, fats and waxes, tails and terpenes.
"If the pilot program proves to be a success, we expect our proprietary process will give us a strong competitive cost advantage in bulk distillate and vape cartridge sales," said Halo COO and Co-Founder Andreas Met. "The Company’s proprietary remediation process can potentially take unusable product that maybe rife with pesticides and transform it into product that is clean and passes quality and safety tests. In doing so, product thought to be a total loss could be reclaimed and sold for full value."
Halo, known for specializing in extractions, is also re-opening its bulk distillate manufacturing enterprises in Cathedral City, California.
Lastly, it's working to acquire a North Hollywood cannabis dispensary.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving—don’t get left behind!
Curious about what’s next for the industry and how to stay ahead in today’s competitive market?
Join top executives, investors, and industry leaders at the Benzinga Cannabis Capital Conference in Chicago on June 9-10. Dive deep into market-shaping strategies, investment trends, and brand-building insights that will define the future of cannabis.
Secure your spot now before prices go up—this is where the biggest deals and connections happen!